Abstract:Olfactory receptor 1393 (Olfr1393) is a G‐protein coupled receptor ectopically expressed in the murine kidney and liver that has functionality in glucose reabsorption via the sodium‐glucose linked‐transporters (Sglts). Due to the recent therapeutic advances regarding inhibition of the Sglts for both type 1 (T1D) and type 2 (T2D) diabetes, we sought to elucidate the contribution of Olfr1393 to the development and progression of the disease. Previously, we determined that Olfr1393 knockout (KO) mice exhibit improved glucose tolerance and attenuated glomerular hyperfiltration when challenged with a high fat diet (60% kcal from fat) to induce early stages of T2D as compared to their wildtype (WT) counterparts. This was linked to the reduced expression of SGLT2 within the proximal tubule of the KO mice. To determine if Olfr1393 is also involved in T1D, both KO and WT mice were challenged with low‐dose injections of Streptozotocin (STZ; 55 mg/kg BW) or vehicle control (PBS; 55 mg/kg BW) for 5 days to induce depletion of pancreatic β cells. In as little as 2 weeks, both KO and WT male STZ‐treated mice presented with hyperglycemia (2hr fasting blood glucose; WT STZ ‐ 433 ± 32.6 mg/dL, KO STZ ‐ 309 ± 22.6 mg/dL, WT V ‐ 169.7 ± 7.96 mg/dL, KO V ‐ 169.6 ± 10.9 mg/dL), although this hyperglycemia was significantly attenuated in KO mice (p < 0.005). At five weeks, this change was even more pronounced with a significant improvement in hyperglycemia noted even after an overnight fast (WT STZ ‐ 473 ± 28.35 mg/dL, KO STZ ‐ 300 ± 36.24 mg/dL). This improved phenotype is not a result of decreased sensitivity to STZ as islet cell area is similar between STZ‐treated KOs and WTs (WT STZ ‐ 4218 ± 826.5 um2, KO STZ ‐ 4913 ± 2335 um2). The improvement in blood glucose levels also correlated with a significant improvement in glucose tolerance noted in the diabetic KO mice (AUC: WT STZ ‐ 35471 ± 3279, KO STZ ‐ 2868 ± 2118; p<0.01). Notably, all improvement was seen in the male mice as STZ induced a sex dependent phenotype of T1D with female mice found to be resistant to the development of hyperglycemia (2hr fasting blood glucose; WT STZ ‐ 167.7 ± 29.16 mg/dL, KO STZ ‐ 178.0 ± 31.92 mg/dL, WT V ‐ 131.0 ± 38.59 mg/dL, KO V ‐ 144.4 ± 15.92 mg/dL). Contrary to data obtained in our T2D model, neither diabetic WT nor KO mice presented with the commonly noted diabetes‐induced hyperfiltration as measured by transdermal clearance of FITC‐sinistrin; this tracked with a lack of an alteration in glomerular area or morphology as assessed by PAS histological analysis. Additionally, we did not detect any changes in plasma electrolytes (iSTAT Chem8+) or blood pressure (via tail cuff BP‐2000 Blood Pressure Analysis System). Given the improved diabetic phenotype, efforts are currently underway to determine if loss of Olfr1393 leads to changes in the expression or localization of renal SGLT1 and/or SGLT2 in the setting of T1D. Collectively, our data has uncovered a novel regulator of glucose handling, and sheds light on how the modulation of this pathway influences the development of diabetes. NIDDK

Progression of diabetes is associated with changes in the ileal transcriptome and ileal‐colon morphology in the UC Davis Type 2 Diabetes Mellitus rat

Colonic epithelial hypoxia remains constant during the progression of diabetes in male UC Davis type 2 diabetes mellitus rats

Systemic Perturbations Of Key Metabolites In Diabetic Rats During The Evolution Of Diabetes Studied By Urine Metabonomics

Modulation of the diet and gastrointestinal microbiota normalizes systemic inflammation and β-cell chemokine expression associated with autoimmune diabetes susceptibility

Dysregulations of Intestinal and Colonic UDP-glucuronosyltransferases in Rats with Type 2 Diabetes.

Two Key Intestinal Features of Type 2 Diabetes in Goto–Kakizaki Rats

Gut mycobiome dysbiosis in rats showing retinal changes indicative of diabetic retinopathy

The gut microbiota contributes to the modulation of intestinal CYP3A1 and P-gp in streptozotocin-induced type 1 diabetic rats

Investigation of Gut Microbiome Changes in Type 1 Diabetic Mellitus Rats Based on High-Throughput Sequencing.

Abnormal Gut Microbiota Composition Contributes to the Development of Type 2 Diabetes Mellitus in Db/db Mice

Distinct alterations of gut morphology and microbiota characterize accelerated diabetes onset in nonobese diabetic mice

Alteration of Intestinal Microbiota in 3-Deoxyglucosone-induced Prediabetic Rats.

Mutual modulation of gut microbiota and the immune system in type 1 diabetes models

Elucidating the Mechanism for Renal Olfactory Receptor 1393’s Attenuated Type 1 Diabetic Phenotype

Type 1 diabetes human enteroid studies reveal major changes in the intestinal epithelial compartment

Controls Of Hyperglycemia Improves Dysregulated Microbiota In Diabetic Mice

Modulation of gut microbiota contributes to effects of intensive insulin therapy on intestinal morphological alteration in high-fat-diet-treated mice

Analysis of immunohistomorphological changes in the colonic mucosa in a high-saturated fat and high-cholesterol fed streptozotocin/nicotinamide diabetic rat model

Histomorphometry Changes and Decreased Reactivity to Angiotensin II in the Ileum and Colon of Streptozotocin-Induced Diabetic Rats

Single-Cell Transcriptomics Reveals That Metabolites Produced by Paenibacillus bovis sp. nov. BD3526 Ameliorate Type 2 Diabetes in GK Rats by Downregulating the Inflammatory Response

Correlation of Differentially Expressed lncRNAs with Intestinal Flora Imbalance, Small Intestinal Permeability, and Glucose Uptake in T2DM Mice